Inborn errors of metabolism
Inborn errors of metabolism form a large class of
Classification and symptoms of metabolic diseases
Traditionally the inherited metabolic diseases were classified as disorders of carbohydrate metabolism, amino acid metabolism, organic acid metabolism, or lysosomal storage diseases.[4] In recent decades, hundreds of new inherited disorders of metabolism have been discovered and the categories have proliferated. Following are some of the major classes of congenital metabolic diseases, with prominent examples of each class.[5]
- Disorders of carbohydrate metabolism
- Disorders of amino acidmetabolism
- phenylketonuria
- tyrosinemia
- maple syrup urine disease
- glutaric acidemia type 1
- Urea Cycle Disorder or Urea Cycle Defects
- Disorders of organic acidurias)
- Disorders of mitochondrialmetabolism
- Disorders of porphyrin metabolism
- Disorders of purine or pyrimidine metabolism
- Disorders of steroid metabolism
- Disorders of mitochondrialfunction
- Disorders of peroxisomalfunction
- Lysosomal storage disorders
Because of the enormous number of these diseases the wide range of systems affected badly, nearly every "presenting complaint" to a healthcare provider may have a congenital metabolic disease as a possible cause, especially in childhood and adolescence. The following are examples of potential manifestations affecting each of the major organ systems.
- Growth failure, failure to grow, loss of weight
- Ambiguous genitalia, delayed puberty, precocious puberty
- Developmental delay, seizures, dementia, encephalopathy, stroke
- pain agnosia
- Skin pigmentation, lacking of pigmentation, excessive hair growth, lumps and bumps
- Dental abnormalities
- Immunodeficiency, low platelet count, low red blood cell count, enlarged spleen, enlarged lymph nodes
- Many forms of cancer
- Recurrent vomiting, diarrhea, abdominal pain
- Excessive urination, kidney failure, dehydration, edema
- Low blood pressure, heart failure, enlarged heart, hypertension, myocardial infarction
- Liver enlargement, jaundice, liver failure
- Unusual facial features, congenital malformations
- Excessive breathing (hyperventilation), respiratory failure
- Abnormal behavior, depression, psychosis
- Joint pain, muscle weakness, cramps
- diabetes mellitus
Diagnostic
Dozens of congenital metabolic diseases are now detectable by
Common screening tests used in the last sixty years:
- Ferric chloride test (detects abnormal metabolites in urine)
- Ninhydrin paper chromatography (detects abnormal amino acid patterns)
- Guthrie test(detects excessive amounts of specific amino acids in blood) The dried blood spot can be used for multianalyte testing using Tandem Mass Spectrometry (MS/MS). This given an indication for a disorder. The same has to be further confirmed by enzyme assays, IEX-Ninhydrin, GC/MS or DNA Testing.
- Quantitative measurement of
- IEX-Ninhydrin post-column derivitization liquid ion chromatography (detects abnormal amino acid patterns and quantitative analysis)
- Urine organic acid analysis by gas chromatography–mass spectrometry
- Plasma acylcarnitine analysis by mass spectrometry
- Urine purine and pyrimidine analysis by gas chromatography-mass spectrometry
Specific diagnostic tests (or focused screening for a small set of disorders):
- Tissue biopsy: liver, muscle, brain, bone marrow
- Skin biopsy and fibroblast cultivation for specific enzyme testing
- Specific DNA testing
A 2015 review reported that even with all these diagnostic tests, there are cases when "biochemical testing, gene sequencing, and enzymatic testing can neither confirm nor rule out an IEM, resulting in the need to rely on the patient's clinical course".
Treatment
In the middle of the 20th century the principal treatment for some of the
- Dietary restriction
- E.g., reduction of dietary protein remains a mainstay of treatment for amino acid disorders
- E.g., reduction of dietary protein remains a mainstay of treatment for
- Dietary supplementation or replacement
- E.g., oral ingestion of cornstarch several times a day helps prevent people with glycogen storage diseases from becoming seriously hypoglycemic.
- Medications
- E.g., metabolites for patients with Tyrosinemia Type I and enables normal growth and development in combination with a low-protein diet
- E.g.,
- Vitamins
- E.g., thiamine supplementation benefits several types of disorders that cause lactic acidosis.
- Intermediary metabolites, compounds, or drugs that facilitate or retard specific metabolic pathways
- Dialysis
- Pompe disease
- Gene therapy
- Bone marrow or organ transplantation
- Treatment of symptoms and complications
- Prenatal diagnosis
Epidemiology
In a study in
Type of inborn error | Incidence | |
---|---|---|
Disease involving amino acids (e.g. PKU, Tyrosinemia), organic acids, primary lactic acidosis, galactosemia, or a urea cycle disease |
24 per 100 000 births[9] | 1 in 4,200[9] |
Lysosomal storage disease | 8 per 100 000 births[9] | 1 in 12,500[9] |
Peroxisomal disorder | ~3 to 4 per 100 000 of births[9] | ~1 in 30,000[9] |
Respiratory chain-based mitochondrial disease | ~3 per 100 000 births[9] | 1 in 33,000[9] |
Glycogen storage disease | 2.3 per 100 000 births[9] | 1 in 43,000[9] |
References
- ^ MedlinePlus Encyclopedia: Inborn errors of metabolism
- ^ "Inherited metabolic disorders - Symptoms and causes". Mayo Clinic.
- ]
- OCLC 884592549.
- ISBN 978-88-470-1119-9.
- PMID 11261724.
- PMID 26075348.
- S2CID 243983688.
- ^ S2CID 30266513.
- PMID 28302345.
Further reading
- Price, Nicholas C; Stevens, Lewis (1996). Principi di enzimologia [Principles of enzymology] (in Italian). A. Delfino. OCLC 879866185.
- Mazzucato, Fernando; Giovagnoni, Andrea (2019). Manuale di tecnica, metodologia e anatomia radiografica tradizionali [Manual of traditional radiographic technique, methodology and anatomy] (in Italian). Piccin. OCLC 1141547603.
- Torricelli, P; Antonelli, F; Ferorelli, P; Borromeo, I; Shevchenko, A; Lenzi, S; De Martino, A (March 2020). "Oral nutritional supplement prevents weight loss and reduces side effects in patients in advanced lung cancer chemotherapy". Amino Acids. 52 (3): 445–451. S2CID 211053578.